More than 11 million people around the world live with Parkinson’s, an age-related neurological condition that causes tremors, difficulty moving and can come with symptoms such as fatigue, insomnia, memory loss and impaired ability to concentrate.
The FDA has approved a new Parkinson’s drug that was based on research by UVA Health scientists.
The drug tavapadon, now branded Juvmo, was pioneered by UVA School of Medicine Professor Richard B. Mailman.
Xuemei Huang, chair of the Department of Neurology, also played a key role in the first successful clinical trial with a drug of this class.
Finding better ways to treat complex diseases is a major mission of UVA’s Paul and Diane Manning Institute of Biotechnology.
The institute aims to more quickly translate UVA’s cutting-edge science into new drugs and treatments to benefit patients across Virginia and beyond.
Early drugs in the class, called D1 agonists, could only be injected, but Juvmo is taken as a pill once per day.
The current gold-standard Parkinson’s medication, levodopa, requires multiple doses per day at increasingly frequent intervals as the disease progresses.
“The gold standard drug for nearly 60 years has been levodopa, available in many forms. Unfortunately, it requires some of the very nerve cells that are dying in Parkinson’s. This means it is harder to use and less effective with time,” Mailman said.
“We figured out the specific mechanism that made levodopa effective, and developed the first drug that could turn on that mechanism. Juvmo itself was made by a brilliant chemist and team who made a similar drug that could be given as a pill only once or twice a day,” Mailman said.
Parkinson’s is driven by the gradual death of nerve cells that make and use the hormone dopamine. No way has been found to stop this degeneration. Juvmo can selectively activate D1 dopamine receptors in the brain, providing relief from some of the disease’s motor symptoms.
The drug’s unique way of working means it may cause fewer side effects than levodopa. While Juvmo can be combined with levodopa, Juvmo also may serve as an important new option for patients for whom the symptoms cannot be optimally controlled.
“Because the target of Juvmo does not degenerate in Parkinson’s disease, the hope is that it will smooth out current problems and also allow symptomatic relief to continue for much longer periods.” Huang said. “Indeed, our own research has suggested that there is hope that it might be helpful for patients in very late stages of PD for whom we do not have effective therapy. With the availability of Juvmo, these ideas can be tested.”
Juvmo will be marketed by the drug company AbbVie and is expected to become available in October.